Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues

Gu,Yifeng; Yang,Peifang; Shao,Qing; Liu,Xia; Xia,Sheng; Zhang,Miaomiao; Xu,Huaxi; Shao,Qixiang

doi:10.3892/ol.2012.1057

Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues

Authors:
- Yifeng Gu
- Peifang Yang
- Qing Shao
- Xia Liu
- Sheng Xia
- Miaomiao Zhang
- Huaxi Xu
- Qixiang Shao
View Affiliations

Affiliations: Department of Immunology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang 212013, P.R. China, Department of Gynecology and Obstetrics, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, P.R. China, Zhenjiang Key Laboratory of Medical Diagnosis, Zhenjiang 212001, Jiangsu, P.R. China
Published online on: December 3, 2012 https://doi.org/10.3892/ol.2012.1057
Pages: 452-458

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have reported that DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) are involved in the epigenetic regulation of cancer, as well as promoting cell proliferation and tumorigenesis. These mechanisms also play important roles in ovarian cancer, but little is known concerning the correlation of DNMTs and HDACs in ovarian cancer. In the present study, we used quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemical staining to examine the mRNA and protein expression of DNMTs and class I HDACs of tissues from 22 cases of ovarian cancer and 8 normal ovaries as a control. Furthermore, we assessed the correlation with clinicopathological stages and the mRNA expression of these genes. The results indicated that the mRNA expression of DNMT1, DNMT3b and class I HDACs was increased in ovarian cancers, while the expression of DNMT3a was not different between cancer tissues and normal ovaries. Additionally, the results of immunohistochemical staining demonstrated that DNMT1 and DNMT3b were significantly increased in ovarian cancer samples. Furthermore, the expression of DNMT1, DNMT3b, HDAC1 and HDAC2 was significantly higher in stage III/IV compared with stage I/II ovarian carcinomas. The expression of HDAC2 was positively correlated with HDCA1, HDAC3 and HDAC8, and DNMT1 was positively correlated with DNMT3b. Simultaneously, DNMT3b was correlated with HDAC1 and HDAC2. HDAC1 may upregulate the expression of DNMTs, but this requires confirmation by in vitro and in vivo experiments. The overall high rate of expression for class I HDACs, DNMT1 and DNMT3b suggested that these mRNAs should be explored as predictive factors in ovarian cancer. In addition, HDAC1, HDAC2 and DNMT3b cooperated in controlling ovarian cancer progression. Determining the correlations between HDACs and DNMTs in ovarian cancer will not only further clarify the mechanisms of genesis and development, but also guide clinical therapy using the inhibitors of HDACs and DNMTs.

View Figures

View References

1.	Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J and Munkarah AR: Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 189:1120–1127. 2003. View Article : Google Scholar : PubMed/NCBI
2.	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
3.	Liu CM: Cancer of the ovary. N Engl J Med. 352:1268–1269; author reply 1268–1269. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Kwon MJ and Shin YK: Epigenetic regulation of cancer-associated genes in ovarian cancer. Int J Mol Sci. 12:983–1008. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Li E, Bestor TH and Jaenisch R: Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell. 69:915–926. 1992. View Article : Google Scholar : PubMed/NCBI
6.	Li E, Beard C and Jaenisch R: Role for DNA methylation in genomic imprinting. Nature. 366:362–365. 1993. View Article : Google Scholar : PubMed/NCBI
7.	Okano M, Bell DW, Haber DA and Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 99:247–257. 1999. View Article : Google Scholar : PubMed/NCBI
8.	Weber M, Hellmann I, Stadler MB, et al: Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 39:457–466. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
10.	Gu W and Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90:595–606. 1997. View Article : Google Scholar : PubMed/NCBI
11.	Marzio G, Wagener C, Gutierrez MI, Cartwright P, Helin K and Giacca M: E2F family members are differentially regulated by reversible acetylation. J Biol Chem. 275:10887–10892. 2000. View Article : Google Scholar : PubMed/NCBI
12.	Ammanamanchi S, Freeman JW and Brattain MG: Acetylated sp3 is a transcriptional activator. J Biol Chem. 278:35775–35780. 2003. View Article : Google Scholar : PubMed/NCBI
13.	de Ruijter AJ, van Gennip AH, Caron HN, Kemp S and van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 370(Pt 3): 737–749. 2003.PubMed/NCBI
14.	Gregoretti IV, Lee YM and Goodson HV: Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 338:17–31. 2004. View Article : Google Scholar : PubMed/NCBI
15.	Mizuno S, Chijiwa T, Okamura T, et al: Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 97:1172–1179. 2001. View Article : Google Scholar : PubMed/NCBI
16.	Yang B, Guo M, Herman JG and Clark DP: Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol. 163:1101–1107. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Girault I, Tozlu S, Lidereau R and Bièche I: Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res. 9:4415–4422. 2003.PubMed/NCBI
18.	Ahluwalia A, Hurteau JA, Bigsby RM and Nephew KP: DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol. 82:299–304. 2001.PubMed/NCBI
19.	Omisanjo OA, Biermann K, Hartmann S, et al: DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer. Histochem Cell Biol. 127:175–181. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Weichert W: HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 280:168–176. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Weichert W, Röske A, Gekeler V, et al: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 98:604–610. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Zhou Q, Agoston AT, Atadja P, Nelson WG and Davidson NE: Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res. 6:873–883. 2008. View Article : Google Scholar : PubMed/NCBI
23.	You JS, Kang JK, Lee EK, et al: Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene. 27:1376–1386. 2008. View Article : Google Scholar
24.	Fuks F, Burgers WA, Brehm A, Hughes-Davies L and Kouzarides T: DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet. 24:88–91. 2000. View Article : Google Scholar : PubMed/NCBI
25.	Boumber Y and Issa JP: Epigenetics in cancer: what’s the future? Oncology (Williston Park). 25:220–226. 228:2011.
26.	Marks PA: Epigenetic targeted anti-cancer drugs: an unfolding story. Oncology (Williston Park). 25:2312352011.PubMed/NCBI
27.	Benda JA and Zaino R: GOG Pathology Manual. Buffalo, NY: Gynecologic Oncology Group; 1994
28.	Staging announcement: FIGO cancer committee. Gynecol Oncol. 25:41986.
29.	Tsankova N, Renthal W, Kumar A and Nestler EJ: Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci. 8:355–367. 2007. View Article : Google Scholar
30.	Halusková J: Epigenetic studies in human diseases. Folia Biol (Praha). 56:83–96. 2010.
31.	Mandrekar P: Epigenetic regulation in alcoholic liver disease. World J Gastroenterol. 17:2456–2464. 2011. View Article : Google Scholar : PubMed/NCBI
32.	Brait M and Sidransky D: Cancer epigenetics: above and beyond. Toxicol Mech Methods. 21:275–288. 2011. View Article : Google Scholar : PubMed/NCBI
33.	Ferguson LR, Tatham AL, Lin Z and Denny WA: Epigenetic regulation of gene expression as an anticancer drug target. Curr Cancer Drug Targets. 11:199–212. 2011. View Article : Google Scholar : PubMed/NCBI
34.	Chen H, Hardy TM and Tollefsbol TO: Epigenomics of ovarian cancer and its chemoprevention. Front Genet. 2:672011. View Article : Google Scholar : PubMed/NCBI
35.	Maldonado L and Hoque MO: Epigenomics and ovarian carcinoma. Biomark Med. 4:543–570. 2010. View Article : Google Scholar : PubMed/NCBI
36.	Abbas A and Gupta S: The role of histone deacetylases in prostate cancer. Epigenetics. 3:300–309. 2008. View Article : Google Scholar : PubMed/NCBI
37.	Weichert W, Denkert C, Noske A, et al: Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 10:1021–1027. 2008.PubMed/NCBI
38.	Hayashi A, Horiuchi A, Kikuchi N, et al: Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer. 127:1332–1346. 2010. View Article : Google Scholar : PubMed/NCBI
39.	Song J, Noh JH, Lee JH, et al: Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 113:264–268. 2005. View Article : Google Scholar : PubMed/NCBI
40.	Sun L, Hui AM, Kanai Y, Sakamoto M and Hirohashi S: Increased DNA methyltransferase expression is associated with an early stage of human hepatocarcinogenesis. Jpn J Cancer Res. 88:1165–1170. 1997. View Article : Google Scholar : PubMed/NCBI
41.	Braconi C, Huang N and Patel T: MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology. 51:881–890. 2010.PubMed/NCBI
42.	Wang L, Zou X, Berger AD, et al: Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res. 1:62–71. 2009.PubMed/NCBI
43.	Tariq M, Saze H, Probst AV, Lichota J, Habu Y and Paszkowski J: Erasure of CpG methylation in Arabidopsis alters patterns of histone H3 methylation in heterochromatin. Proc Natl Acad Sci USA. 100:8823–8827. 2003. View Article : Google Scholar : PubMed/NCBI
44.	Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP and Kouzarides T: The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem. 278:4035–4040. 2003. View Article : Google Scholar : PubMed/NCBI